FDA warns against long-term azithromycin use for some

FDA warns against long-term azithromycin use for some

(HealthDay)—The U.S. Food and Drug Administration is warning patients with cancers of the blood or lymph nodes who undergo a donor stem cell transplant not to take azithromycin, as long-term use of the antibiotic has been associated with increased risk of cancer relapse.

In a clinical trial, azithromycin was being used to prevent bronchiolitis obliterans syndrome in patients with cancers of the blood or lymph nodes who underwent a donor stem cell transplant. However, long-term use of the antibiotic was tied to cancer relapse and death.

"Health care professionals should not prescribe long-term azithromycin for prophylaxis of bronchiolitis obliterans syndrome to patients who undergo donor because of the increased potential for and death," the agency said in a statement.

Health care professionals and patients are encouraged to report adverse events or side effects related to the use of azithromycin to the FDA's MedWatch Safety Information and Adverse Event Reporting Program.


Explore further

Azithromycin tied to poor airflow decline-free survival after HSCT

More information: More Information
MedWatch Reporting

Copyright © 2018 HealthDay. All rights reserved.

Citation: FDA warns against long-term azithromycin use for some (2018, August 13) retrieved 21 November 2019 from https://medicalxpress.com/news/2018-08-fda-long-term-azithromycin.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
2 shares

Feedback to editors

User comments